Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3830589 | 0.97 | HSD17B10 (0.45) | HSD17B10CHRNA7KMT2AHSD11B1SMN1; SMN2 | |
| SCHEMBL9532947 | 0.85 | — | — | |
| Fluorobenzene SCHEMBL27599288 | 0.81 | CHRNA7 (0.49) | CHRNA7KMT2AHSD11B1ALDH1A1 | |
| SCHEMBL3947375 | 0.80 | DRD2 (0.44) | HSD17B10NPC1POLBRAB9AGAA | |
| SCHEMBL21056391 | 0.80 | KMT2A (0.43) | HSD17B10KMT2AHSD11B1SMN1; SMN2 | |
| SCHEMBL27292118 | 0.80 | CHRM5 (0.36) | HSD17B10HSD11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4915224 | 0.77 | GNAI3 (0.44) | HSD17B10 | |
| SCHEMBL84808 | 0.76 | CHRNA7 (0.48) | CHRNA7KMT2AHSD11B1SMN1; SMN2GAA | |
| SCHEMBL262312 | 0.76 | — | — | |
| SCHEMBL6657817 | 0.76 | CHRNA7 (0.48) | CHRNA7KMT2AHSD11B1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | claimed |
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | claimed |
| CN-111606908-B | JAK inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | claimed |
| CN-111954532-A | Anti-tumor multi-drug resistance of heteroaryl amide compounds, application of heteroaryl amide compounds in treating cancer and protein-drug molecular compound | 上海交通大学医学院附属瑞金医院 | 2020-11-17 | — | — | CN | claimed |
| CN-111511730-A | Amide substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | claimed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-02 | — | — | US | claimed |
| CN-111295387-A | Heteroaryl amide compound, preparation method thereof, medicinal composition and application thereof | 上海交通大学医学院附属瑞金医院 | 2020-06-16 | — | — | CN | claimed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | claimed |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-20040166125-A1 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-26 | — | — | US | claimed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | claimed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | claimed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | claimed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | claimed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | claimed |
| US-5290807-A | Antiinflammatory agents | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | HSD17B10 413/4885CHRNA7 2823/4885KMT2A 3970/4885 |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | HSD17B10 1011/4885CHRNA7 2754/4885KMT2A 3433/4885 |
| US-20040166125-A1 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | XDH, CALCRL, CALCA | HSD17B10 2131/4885CHRNA7 1743/4885KMT2A 4610/4885 |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | HSD17B10 2077/4885CHRNA7 3733/4885KMT2A 4045/4885 |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | HSD17B10 1643/4885CHRNA7 4818/4885KMT2A 2015/4885 |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | HSD17B10 573/4885CHRNA7 2817/4885KMT2A 3766/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | HSD17B10 1011/4885CHRNA7 2754/4885KMT2A 3433/4885 |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | HSD17B10 4186/4885CHRNA7 4870/4885KMT2A 883/4885 |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | HSD17B10 1643/4885CHRNA7 4818/4885KMT2A 2015/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | HSD17B10 897/4885CHRNA7 4237/4885KMT2A 3251/4885 |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | HSD17B10 1093/4885CHRNA7 2898/4885KMT2A 2813/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | HSD17B10 4186/4885CHRNA7 4870/4885KMT2A 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.